What insurance policy changes affect HCPCS G0452?

There are 11 tracked policy changes affecting HCPCS G0452, including updates from Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS G0452?

Payers that have issued tracked updates for HCPCS G0452 include: Independence Blue Cross.

How do I get notified when HCPCS G0452 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS G0452. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS G0452?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

G0452 — Molecular pathology procedure; physician interpretation and report: Insurance Policy Changes

G0452 Insurance Policy Changes

HCPCS G0452 is officially defined as "Molecular pathology procedure; physician interpretation and report." HCPCS G0452 is referenced in 11 tracked payer policy changes from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0452 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

06.02.10r, Genetic Testing for Inherited Susceptibility to Colon Cancer and Microsatellite Instability Testing (Familial Adenomatous Polyposis and Lynch Syndrome) (Independence Administrators)

Independence Blue Cross·Identified Sep 17, 2026

This is a reissue with no substantive changes to Independence Administrators' genetic testing policy for inherited colon cancer susceptibility (FAP and Lynch syndrome). However, the disclaimer language was updated to clarify that this policy only applies to members whose groups have NOT enrolled in the UM vendor program; those enrolled in the eviCore Lab Management Program should refer to that policy instead. Billing teams must verify member enrollment status before processing genetic testing claims.

G0452 Insurance Policy Changes

06.02.10r, Genetic Testing for Inherited Susceptibility to Colon Cancer and Microsatellite Instability Testing (Familial Adenomatous Polyposis and Lynch Syndrome) (Independence Administrators)

06.02.09g, Human Immunodeficiency Virus (HIV) Genotyping and Phenotyping (Independence Administrators)

06.02.10r, Genetic Testing for Inherited Susceptibility to Colon Cancer and Microsatellite Instability Testing (Familial Adenomatous Polyposis and Lynch Syndrome) (Independence Administrators)

06.02.29d, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)

06.02.29g, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)

06.02.09g, Human Immunodeficiency Virus (HIV) Genotyping and Phenotyping (Independence Administrators)

06.02.29g, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)

MA06.014e, Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy

MA06.014e, Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy

06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)

06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)